Aspen Neuroscience is developing ANPD001, an autologous iPSC-derived neuron replacement therapy for Parkinson's disease currently in Phase 1/2a clinical trials.
Artificial Intelligence is transforming regenerative medicine by analyzing millions of chemical compounds rapidly, significantly reducing drug discovery time and costs while improving precision.